Investor Spotlight: Emerillon Capital

May 4 2017

Are you looking for a partner who can adapt to your venture project?

On May 4th, JLABS @ Toronto invites Emerillon Capital Investment Director, Nicola Urbani, to our “Investor Spotlight” to discuss:

  • Practical tips on what he looks for in a pitch
  • Emerillon Capital’s areas of interest – what are they investing in?
  • Case studies of successful investments
  • How to increase your chances of successful fundraising

Launched in Montreal in June 2013, Emerillon Capital (backed by its lead financial sponsor CM-CIC Investissement) is a venture capital fund with a patient capital and flexible approach. It is dedicated to supporting and investing in companies positioned in expanding sectors showing strong potential for growth. Emerillon is specialized in equity (or quasi-equity) investments and support of companies with strong technological expertise in their early development phases: pre-revenue, commercial start-up and first expansion.

If interested in meeting one-on-one with Nicola after his presentation, please fill out an application here:

10:30 AM | Registration and Networking
11:00 AM | Presentation and Q&A
12:00 PM | Networking and Lunch
12:30 PM - 5:00 PM | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on April 13, 2017.

$15 | General Public
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on May 3rd (or sold out).

JLABS @ Toronto
661 University Ave, Suite 1300
Toronto, Ontario

Nicola Urbani | Investment Director, Emerillon Capital
A management and investment professional with a passion for innovation and broad experience (13 years) in venture capital investment in life sciences and cleantech industries. Worked in two different venture capital Fund managers with a total committed capital of over $400M: GeneChem management (with 4 different Funds targeting different stages and indications: GeneChem Technologies, GeneChem Therapeutics, AgeChem Financial, and AmorChem Financial) and Emerillon Capital. Served on numerous Boards and helped shape company strategies, C-level management teams and Board committees. Active involvement in the growth of several companies developing therapeutics through human clinical trials, and participated in numerous financing rounds with top tier Canadian and international venture capital Funds. Led several in-and out-licensing deals in life sciences and cleantech.
Immediately prior to joining Emerillon, Nicola was VP Commercialization at the McGill-affiliated Jewish General Hospital in Montreal, where he was responsible for technology transfer and the creation of companies. Nicola has a PhD in molecular genetics from McGill University and an MBA from Université du Québec à Montréal.
Connect with Nicola:   Connect on LinkedIn